Vexev develops an autonomous robotic imaging platform, VxWave, that combines robotics, artificial intelligence and ultrasound to automate vascular ultrasound acquisition. Its initial application is upper-limb imaging for dialysis vascular access, with plans to expand into other vascular disease areas such as cardiovascular and peripheral artery disease. The company reported a 94% scanning success rate for autonomous vascular imaging by non-specialist clinical staff in a multi-site study with U.S. Renal Care. VxWave is an investigational device and Vexev is pursuing FDA 510(k) clearance to enable U.S. commercialization. Vexev has raised $19 million in total funding to date and intends to use recent proceeds to support regulatory activities, manufacturing scale-up and commercialization. The company emphasizes building clinical evidence to support future AI-enabled decision tools.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2026